Hormone Replacement Therapy vs. BHRT: Understanding the Difference

The terms do not mean the same thing

Hormone replacement therapy, or HRT, describes treatment that supplies a hormone for a defined medical purpose. Bioidentical hormone therapy, often shortened to BHRT, describes hormones whose molecular structure is the same as a hormone made by the body. One term describes a treatment approach; the other describes a chemical characteristic. “Bioidentical” does not automatically mean compounded, plant-based, safer, or more effective. Some FDA-approved products use bioidentical estradiol or progesterone, while compounded preparations are made for an individual and do not receive FDA approval for safety, effectiveness, or quality before marketing. The American College of Obstetricians and Gynecologists’ menopause guidance provides useful patient context.

What FDA approval tells you

An FDA-approved hormone product has an approved label describing its active ingredient, strength, route, indication, contraindications, warnings, and adverse reactions. Approval does not mean it is right for every patient, but it gives a clinician and patient a defined evidence base. A compounded product can be appropriate in limited circumstances when an FDA-approved option cannot meet a documented need, yet the prescriber should explain why. A pharmacy’s ability to customize a formulation is not the same as a regulator’s finding that the formulation is safe and effective for a particular claim.

Why “natural” is an incomplete safety argument

Many hormones begin with plant-derived raw materials, but the finished medicine is evaluated by its active ingredient, dose, route, manufacturing, and clinical evidence. Natural origin does not prevent blood clots, gallbladder problems, breast effects, abnormal uterine bleeding, or interactions. Likewise, a synthetic molecule can be chemically identical to a human hormone. Ask for the exact ingredient and product name instead of relying on a marketing label. A clinician should be able to explain what is known about that formulation and what remains uncertain.

Menopause treatment depends on symptoms and risk

Menopausal hormone therapy may help vasomotor symptoms such as hot flashes and night sweats, and it can help certain genitourinary symptoms. It is not a universal anti-aging treatment or a guaranteed way to prevent chronic disease. The decision depends on age, time since menopause, symptom severity, uterus status, personal and family history, clotting risk, migraine pattern, liver disease, and patient preferences. People with a uterus generally need an endometrial-protective progestogen when systemic estrogen is used. Local vaginal products have different exposure and indications from systemic therapy.

Warnings are product-specific

In February 2026, FDA approved updated labeling for an initial group of menopause hormone products, removing certain cardiovascular, breast-cancer, and dementia statements from their boxed warnings. That change does not make hormone therapy risk-free. The boxed warning about endometrial cancer remains relevant to systemic estrogen-alone therapy, and the exact product label must still guide the discussion.

Hormone labels carry important warnings, and the wording can change as evidence and regulatory review evolve. Risks may differ by route, dose, timing, and whether estrogen is combined with a progestogen. Breast cancer history, unexplained vaginal bleeding, prior clot or stroke, coronary disease, liver disease, and pregnancy may change the risk discussion or make a product inappropriate. Do not apply a warning from one cream, tablet, patch, or pellet to every hormone product. Read the current label and review it with the prescriber. Unexpected bleeding, chest pain, shortness of breath, one-sided leg swelling, or neurologic symptoms need prompt medical attention.

Compounded BHRT deserves careful questions

Compounded capsules, creams, troches, or pellets may be marketed as more individualized, but a custom formulation is not automatically more precise. Absorption can vary by route and product, and some compounded preparations are not tested in the same way as an approved medicine. Ask whether an FDA-approved product could meet the goal, who measures the active ingredient, how the pharmacy checks potency, what monitoring is planned, and what will happen if symptoms do not improve. Saliva or urine hormone testing marketed to select a dose is not a substitute for a clinical assessment.

Men and women need individualized evaluation

Men may ask about testosterone when libido, energy, or erections change. The FDA information on testosterone products emphasizes that treatment is for appropriately evaluated men with a medical cause of deficiency, not a general vitality promise. Women may need a different evaluation for fatigue, low desire, sleep disruption, or vaginal symptoms. Symptoms overlap with thyroid disease, anemia, depression, sleep apnea, medication effects, and relationship stress. A hormone result alone does not establish the cause.

Route and monitoring change the discussion

Tablets, patches, gels, creams, rings, injections, and pellets do not create identical exposure. A transdermal route may be considered differently from an oral route when clot risk is relevant, but route is only one part of the decision. Monitoring should focus on symptoms, adverse effects, examination, and any tests that are clinically justified. Repeatedly increasing a hormone because a number is not in a preferred range can expose a person to risk without improving the original complaint. Review the product, route, and follow-up schedule together.

Reassess rather than assume

Symptoms can improve, persist, or change as menopause and other conditions evolve. A follow-up visit should revisit whether the original indication remains, whether the route is tolerated, and whether a nonhormonal option would now meet the goal. Keep the discussion shared and document questions before renewing a product.

Questions to bring to a visit

Ask which symptom is being treated, whether the product is FDA-approved, what the active ingredients and route are, why that route was chosen, which risks apply to your history, and how follow-up will measure benefit. Tell the clinician about breast or reproductive cancers, clotting events, migraines, liver disease, fertility plans, prescriptions, and supplements. Atlanta Medical Institute provides information about hormone services and bioidentical hormone services; appointment logistics are available through contact. This article is educational. Current labeling and an individual medical assessment should guide treatment decisions.